<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995042</url>
  </required_header>
  <id_info>
    <org_study_id>SHR7280-104</org_study_id>
    <nct_id>NCT04995042</nct_id>
  </id_info>
  <brief_title>A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in&#xD;
      adult patients with hormone sensitive prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, Multicenter, Singel Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events（AEs）</measure>
    <time_frame>30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limited Toxicity (DLT)</measure>
    <time_frame>28 Days (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerable dose (MTD)</measure>
    <time_frame>28 Days (first cycle）</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for phase II (RP2D)</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve in the dosing interval AUC(TAU) of SHR7280</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of SHR7280</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed trough plasma concentration (Ctrough) of SHR7280</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of SHR7280</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum testosterone concentrations</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum luteinizing hormone (LH) concentrations</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum follicle stimulating hormone (FSH) concentrations</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Testosterone Concentrations &lt; 50 ng/dL</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Effective Castration Rate Over 24 Weeks</measure>
    <time_frame>Day 1 of Week 5 to Day 1 of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Effective Castration Rate Over 48 Weeks</measure>
    <time_frame>Day 1 of Week 5 to Day 1 of Week 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Serum Prostate-Specific Antigen Concentration Change frome Baseline at the End of Weeks 4, 8, 12</measure>
    <time_frame>Day 1 of Weeks 5, 9 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate-Specific Antigen Progression</measure>
    <time_frame>30 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hormone Sensitive Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SHR7280 Does Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR7280</intervention_name>
    <description>Drug: SHR7280 All participants receive SHR7280 alone.</description>
    <arm_group_label>SHR7280 Does Escalation and Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and the willingness to sign a written informed consent document；&#xD;
&#xD;
          2. Age ≥18 years old;&#xD;
&#xD;
          3. Histologically or cytologically confirmed prostate adenocarcinoma;&#xD;
&#xD;
          4. Candidate for androgen deprivation therapy (ADT) for the management of&#xD;
             hormone-sensitive prostate cancer；&#xD;
&#xD;
          5. Appropriate serum testosterone and serum PSA concentration at screening as specified&#xD;
             in the protocol；&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1;&#xD;
&#xD;
          7. Adequate organ performance based on laboratory blood tests;&#xD;
&#xD;
          8. Agree to use adequate contraception prior to study entry and for the duration of study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously received gonadotropin-releasing hormone analogues (GnRH-a) for more than 12&#xD;
             months total duration (if GnRH-a was received for 12 months or less, then that GnRH-a&#xD;
             must have been completed washout period prior to the first dose of study drug).&#xD;
&#xD;
          2. Patients who have received chemotherapy for prostate cancer;&#xD;
&#xD;
          3. History of surgical castration;&#xD;
&#xD;
          4. Received Abiraterone acetate with 3 months prior to the first dose of study drug;&#xD;
&#xD;
          5. Receieved molecular target therapy, immunotherapy, androgen receptor blockade, 5-alpha&#xD;
             reductase inhibitors, estrogen, and other investigational compound with 4 weeks prior&#xD;
             to the first dose of study drug;&#xD;
&#xD;
          6. Patients with known or suspected brain metastasis；&#xD;
&#xD;
          7. Diagnosis or treatment for another systemic malignancy within 5 years before study&#xD;
             treatment initiation;&#xD;
&#xD;
          8. Patients with uncontrolled and clinically significant hypertension and diabetes;&#xD;
&#xD;
          9. Known hypersensitivity to SHR7280, SHR7280 excipients,；&#xD;
&#xD;
         10. History of immunodeficiency (including HIV infection) or organ transplantation;&#xD;
&#xD;
         11. Known active hepatitis B or C infection;&#xD;
&#xD;
         12. Other serious accompanying illnesses, which, in the researcher's opinion, could&#xD;
             seriously adversely affect the safety of the treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ran Tao</last_name>
    <phone>+86 021-68868570</phone>
    <email>ran.tao@hengrui.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

